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Parasite infection is associated with Kaposi’s
sarcoma associated herpesvirus (KSHV) in
Ugandan women
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Juliet Ndibazza1, Alison M Elliott1,5†, Denise Whitby4† and Robert Newton2,6†
Abstract
Background: Immune modulation by parasites may influence susceptibility to bacteria and viruses. We examined
the association between current parasite infections, HIV and syphilis (measured in blood or stool samples using
standard methods) and antibodies against Kaposi’s sarcoma herpesvirus (KSHV), measured by ELISA, in 1915 stored
plasma samples from pregnant women in Entebbe, Uganda.
Results: Seroprevalence of KSHV was higher in women with malaria parasitaemia (73% vs 60% p = 0.01),
hookworm (67% vs 56% p = 0.001) and Mansonella perstans (69% vs 59% p = 0.05); seroprevalence increased with
increasing intensity of hookworm infection (p < 0.001[trend]). No associations were found for HIV, five other
parasites or active syphilis. These effects were not explained by socioeconomic status or education.
Conclusions: Specific parasite infections are associated with presence of antibodies against KSHV, perhaps
mediated via their effect on immune function.
Background
Infection with KSHV is the underlying cause of Kaposi’s
sarcoma (KS), although it may not be sufficient [1].
Immune suppression, such as that caused by human
immunodeficiency virus (HIV), significantly increases the
risk of KS among KSHV infected people and is associated
with increased viral load and viral shedding [2-8]. Among
people without HIV infection or other forms of overt
immune suppression, geographic and temporal variation
in the incidence of KS and in the prevalence of KSHV
suggest that cofactors may be important in facilitating
both transmission and disease [9-18]. Whether cofactors
act directly or via effects on the immune system is
unclear [19].
Many environmental co-factors for KSHV transmission
and disease have been suggested, including volcanic soils
[20], limestone [21] and ‘oncoweeds’ - that is plants with
carcinogenic properties or the ability to reactivate KSHV
in vitro - although epidemiologic evidence of a role for
these agents remains scant [22]. Ecological studies in the
Mediterranean area found that eradication of mosquitoes
and other blood sucking arthropods was associated with
declines both in the prevalence of KSHV and in the inci-
dence of KS [9-14,18,23]. The ‘promoter arthropod
hypothesis’ suggests that insect blood feeding increases
KSHV transmission through viral reactivation and KS
through inflammatory mechanisms associated with the
bite [11,14].
Studies of KS in Africa have identified risk factors for KS
that might be common to risk of certain parasites, such as
exposure to water, high rainfall and walking barefoot
[15,24-26]. Previously reported risk factors for KSHV, such
as use of surface rather than piped water, may also be con-
sistent with increased exposure to parasites [27]. Ecological
associations between malaria and KSHV or KS in Africa
are inconclusive [15]. Only one study has attempted to
measure parasite burden among cases with KS and con-
trols; KS patients had a higher carriage of certain intestinal
helminths than did controls [28].
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Parasites impact on immune function [29,30] and
could, therefore, modulate the host response to KSHV.
The association between EBV (another gamma herpes-
virus) and malaria is well documented [31-34]. Parasite-
related immune modulation may increase susceptibility
to KSHV infection and may also be associated with
increased viral shedding and transmission, leading to an
increased prevalence of KSHV infection and increased
incidence of KS. We tested the hypothesis that parasites
may be associated with KSHV by examining associations
between current parasite infections and presence of anti-
bodies against KSHV.
Methods
The investigation was conducted within an existing study
in Uganda - the Entebbe Mother and Baby Study
(EMaBS) - a large on-going double blind randomised pla-
cebo controlled trial designed to determine the impact of
helminth infections and their treatment on vaccine
responses and infectious disease outcomes. Detailed
information about the study design has been reported
elsewhere [35]. Briefly, consenting pregnant women resi-
dent in Entebbe and Katabi were recruited from the gov-
ernment funded antenatal clinic at Entebbe hospital,
Uganda. Blood samples were obtained by venepuncture,
and processed for syphilis, HIV serology, CD4 count and
for examination for malaria parasites and Mansonella
perstans. A stool sample was obtained for examination
for intestinal helminths. Of note, women were apparently
well on the day of enrollment, so infections identified
were essentially asymptomatic. Information was collected
on clinical and socio-demographic variables and socio-
economic status was defined according to a composite
variable comprising information on several relevant
factors [35].
Maternal plasma samples from the enrolment visit-
stored at -80°C at the Uganda Virus Research Institute
(UVRI), Entebbe, Uganda - were identified for 1915
women. KSHV serologic testing was based on ELISA for
recombinant proteins to K8.1, a KSHV structural glyco-
protein expressed during lytic infection, and for ORF 73, a
nuclear antigen expressed during latency as previously
described [36,37]. Each ELISA plate contained three posi-
tive and three negative controls for quality control and
cut-off calculation. Both K8.1 and ORF 73 assay have high
performance accuracy with a sensitivity of 98.78% and
89.02% respectively and specificity of 98.79% and 97.57%
respectively [36]. The ELISAs were performed at the
Uganda Virus Research Institute (UVRI) by the study lead
and a technician, both of whom were blinded to patient
details. The two assays were used to define evidence of
KSHV - individuals were considered to be seropositive if
they were positive to either assay and negative if both
ELISA assays were negative. The assays were transferred
to UVRI from the Viral Oncology Section (VOS), National
Cancer Institute (NCI), USA and analysis of the positive
and negative controls showed comparable performance at
NCI and UVRI. The geometric mean optical density (OD)
of the ORF 73 positive and negative controls was 2.50 and
0.04 respectively at VOS, NCI and 2.62 and 0.06 respec-
tively at UVRI. The K8.1 positive and negative controls
were 2.23 and 0.10 at NCI and 2.22 and 0.06 at UVRI.
Analysis of 375 samples tested in duplicate at both VOS,
NCI and UVRI resulted in Kappa values of 0.89 for the
K8.1 ELISA and 0.86 for the ORF 73 ELISA.
For parasite intensities, hookworm was measured by
egg counts in stool and catogorised as light (< 1,000
eggs per gram (epg) of stool), moderate (1,000 to 3,999
epg) and heavy infection (≥4,000 epg) [35,38]. The
intensity of malaria infection was categorised as being
below ("low”) or above ("high”) the median parasite
count, per 200 white blood cells. For microfilariae, ter-
tiles of the number of filaria per millilitre of blood were
used to categorise into low, medium and high infection
intensity.
Data were analysed using Stata11SE (StataCorp LP,
College Station, Texas, USA). Potential associations
between KSHV seropositivity and each potential risk fac-
tor were estimated using the Pearson chi-squared test or
Fisher’s exact test where expected numbers were small.
Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated using logistic regression modeling con-
trolling for age and other possible confounders. The pos-
sibility of multiple parasite infections increasing risk of
KSHV seropositivity more or less than expected under a
multiplicative model was assessed by fitting terms for
interactions between parasites in the logistic regression
model. The agreement between K8.1 and ORF73 ELISA
assays was assessed formally by calculating a Kappa sta-
tistic. All p values were 2-sided and we considered
p<0.05 to be statistically significant.
Results and Discussion
The median age of women in the study was 23 years (IQR
19-27); most were in the third trimester of pregnancy
(54% (1032/1915) with 46% (879/1915) in the second).
The seroprevalence of HIV was 10% (193/1915) and the
median CD4 count among those who were seropositive
was 551 (IQR 368-796). The highest level of educational
attainment reached by the majority of women was primary
(50% [961/1911]), with 62% (1191/1915) describing them-
selves as unemployed or housewives and 82% (1561/1905)
reporting a personal income of less than 30,000 Ugandan
Shillings (approx. $12USD) per month. The prevalence of
antibodies to K8.1 was 41% and to ORF 73 was 52%. 32%
of women were seropositive to both antigens and 61% had
antibodies to either ORF 73 and/or K8.1. There was mod-
erate concordance between latent KSHV ORF 73 and lytic
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KSHV K8.1 assays in detecting KSHV seropositivity (k =
0.43), consistent with previous studies [37,39]. Prevalence
of antibodies did not change significantly with age,
although the age range of study participants was relatively
narrow. Previous studies of women in a similarly narrow
age range in Africa have showed little or no association
with age [27,37,39,40]. As expected, prevalence decreased
with increasing maternal education and household socioe-
conomic status [27]
Common infections among the participants were hook-
worm (44%), Mansonella perstans (21%), Schistosoma
mansoni (18%), asymptomatic Plasmodium falciparum
parasitaemia (10%) and HIV (10%). The prevalence of anti-
bodies to K8.1, ORF 73, both antigens and either antigen
was 41%, 52%, 32% and 61% respectively. Unadjusted ORs
for the association of infections (including eight current
parasitic infections), socio-demographic and behavioral
factors with antibodies against KSHV are shown in
Table 1. In Table 2, the variables found to be associated
with KSHV serostatus have been examined again with
adjustment for each other. Seropositivity to KSHV was sig-
nificantly associated with malaria parasitaemia, hookworm
and Mansonella perstans. The prevalence of antibodies to
KSHV increased with increasing intensity of hookworm
infection (p < 0.001 [trend]; as measured by egg counts in
stool), from 56% among those with no infection to 67% in
those with light/moderate infection (12 - the limit of
detection - to 3,999 eggs per gram (epg) of stool) to 72%
in those with heavy infection (≥4,000 epg); no consistent
trends were observed for malaria parasite density or Man-
sonella perstans intensity, but most infections were light
(Table 3).
Mode of KSHV transmission is yet to be fully elucidated,
but high acquisition rates during childhood imply a non-
sexual route [7,27,37,40-49]. In studies of mother-child
pairs [37,40,50], the impact of HIV on KSHV seropositivity
is unclear with some studies reporting a positive impact
[37] and others reporting borderline or null association
[40,50]. We observed no statistically significant association
between HIV and KSHV seropositivity. There was no
association between KSHV seropositivity and CD4 count
in HIV infected women (p = 0.13). The lack of association
with syphilis is consistent with previous studies reporting
no association with KSHV and markers of sexual behavior
Table 1 Crude associations with antibodies against KSHV and sociodemographic and clinical risk factors among
Ugandan women
Factor Prevalence of women KSHV seropositive* OR (95% CI) P**
Age
14-19 years 65% (288/443) 1
20-24 years 62% (446/717) 0.89 (0.70-1.14)
25-29 years 56% (252/444) 0.71(0.54-0.93)
30-34 years 58% (125/216) 0.74 (0.53-1.03)
> = 35 years 55% (52/94) 0.67 (0.43-1.05) 0.007 [trend]
Maternal education
None 74% (50/68) 1
Primary 64% (617/960) 0.65 (0.37-1.12)
Senior 59% (418/713) 0.51 (0.29-0.89)
Tertiary 45% (76/169) 0.29 (0.16-0.55) <0.001 (trend)
Household SES***
1 (lowest) 69% (75/109) 1
2 71% (112/158) 1.10 (0.65-1.88)
3 64% 369/581) 0.79 (0.51-1.22)
4 58% 310/531) 0.64 (0.41-0.99)
5 57% (222/389) 0.60 (0.38-0.95)
6 (highest) 50% (55/111) 0.45 (0.26-0.77) <0.001 [trend]
HIV
Negative 60% (1033/1721) 1
Positive 67% (130/193) 1.38 (1.00-1.89) 0.04
Malaria parasites
No 60% (1010/1697) 1
Yes 73% (135/185) 1.84 (1.31-2.58) <0.001
Active syphilis
No 61% 1110/1833) 1
Yes 68% (52/76) 1.41 (0.86-2.31) 0.25
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[37,47,51,52]. In unadjusted analyses, the use of insecticide
in the home was associated with a lower prevalence of
antibodies against KSHV (p = 0.005) although use of a bed
net and walking barefoot (a risk factor for hookworm
infection) was not. Effects of increasing numbers of infec-
tions on KSHV seropositivity combined multiplicatively;
there were no interactions between the effects of HIV,
malaria parasitaemia, hookworm or Mansonella perstans
on KSHV infection (results not shown). KSHV seropositiv-
ity was not associated with trimester or pregnancy dura-
tion as measured in months. The results for ORF 73 and
K8.1 separately, did not materially differ.
This study has a number of important limitations. It is
possible that associations arose as a result of residual
confounding by socio-economic status (SES), although
adjustment for certain markers of SES had no effect on
the findings. Furthermore, the work was cross sectional
and so associations identified should be confirmed in
longitudinal studies. Also, the study participants were
pregnant and pregnancy itself may modulate immune
function. However, since all comparisons were internal
within the study (i.e. comparing one group of pregnant
women with another), it is difficult to see how this
could have impacted on the results.
Conclusions
The findings reported here provide evidence of an asso-
ciation between specific parasites and presence of anti-
bodies against KSHV. Specific parasite infections may
increase KSHV replication or cause reactivation, thereby
increasing the likelihood of detecting antibodies against
KSHV. Alternatively, specific parasites may increase sus-
ceptibility to infection - we cannot, in this study, distin-
guish between these two possibilities. Co-factors for
Table 1 Crude associations with antibodies against KSHV and sociodemographic and clinical risk factors among Ugan-
dan women (Continued)
Hookworm
No 56% (594/1070) 1
Yes 67% (562/836) 1.64 (1.36-1.98) <0.001
Mansonella perstans
No 59% (884/1508) 1
Yes 69% (277/402) 1.55 (1.23-1.96) <0.001
Schistosoma mansoni
No 61% (952/1568) 1
Yes 60% (204/338) 1.0 (0.78-1.25) 0.90
Strongyloides stercoralis
No 61% (1007/1665) 1
Yes 63% (144/230) 1.10 (0.82-1.46) 0.54
Trichuris trichiura
No 60% (1044/1739) 1
Yes 67% (112/167) 1.36 (0.97-1.90) 0.07
Ascaris lumbricoides
No 61% (1125/1859) 1
Yes 66% (31/47) 1.27 (0.69-2.33) 0.45
Trichostrongylus species
No 61% (1149/1887) 1
Yes 37% (7/19) 0.38 (0.15-0.96) 0.03
Use of mosquito spray in the home
No 62% (942/1510) 1
Yes 55% (219/400) 0.73(0.58-0.90) 0.005
Use of bed net
No 61% (574/952) 1
Yes 60% (587/959) 1.04 (0.87-1.25) 0.68
Walk barefoot
Yes 61% (925/1505) 1
No 58% (236/407) 1.15 (0.92-1.44) 0.20
* Individuals were considered KSHV positive if they had a positive ORF 73 and/or K8.1 ELISA. Participants were considered negative if both ELISAs were negative.
** All estimated using Chi-squared test except for Trichostrongylus species which was estimated using a Fishers exact test. All tests of statistical significance two
sided.
*** Socio-economic status
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KSHV transmission and disease have been sought to
explain the elevated prevalence of KSHV and incidence
of KS in sub-Saharan Africa. Data presented here sug-
gest that parasites may constitute one such co-factor.
Further epidemiological and laboratory studies are
needed to fully understand the role of parasites as a risk
factor for infection with KSHV.
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